Minneapolis, January 28, 2019/PRNewswire/ — Bio-Techne today announced the launch of the CE-SDS PLUS system for its ProteinSimple-branded Maurice™ platform. This new system further expands the usability of Maurice’s proprietary cartridge and reduces undesirable protein fragmentation during separation. Since its introduction in 2016, Maurice has enabled capillary electrophoresis – sodium dodecyl sulfate (CE-SDS) for size-based... Read more
MINNEAPOLIS, Jan. 24, 2019 /PRNewswire/ — Bio-Techne announces the launch of their cell and gene therapy portfolio. As a leading manufacturer of GMP-grade ancillary materials and automated instrumentation, Bio-Techne is uniquely able to offer solutions that advance the translation of cell and gene therapies, from discovery-level research to the optimization of cell therapy manufacturing unit... Read more
MINNEAPOLIS, Dec. 4, 2018 /PRNewswire/ — Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used stem cell compounds, Y-27632 (ROCK inhibitor) and CHIR 99021. Y-27632 is a ROCK inhibitor used in stem cell cryopreservation, expansion and differentiation protocols to enhance stem cell survival... Read more
OCTOBER 12, 2018 MINNEAPOLIS, Oct. 12, 2018 /PRNewswire/ — Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China. Chuck Kummeth, President and CEO of Bio-Techne, Yan Pingyi, Chairman of Micropoint Bioscience, and Wang Bin, Executive Vice President, Shenzhen Association of Medical Devices, all attended the meeting and signing ceremony. Micropoint... Read more
OCTOBER 02, 2018 MINNEAPOLIS, Oct. 2, 2018 /PRNewswire/ — Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu, Ph.D., was presented with the CE Pharm Award at this year’s CE Pharm meeting, September 9-12, 2018, for his contributions to the capillary electrophoresis (CE) field. Each year since 2006, the CASSS organization has identified an individual... Read more
Download as PDF SEPTEMBER 27, 2018 MINNEAPOLIS, Sept. 27, 2018 /PRNewswire/ — Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing. Through strategic acquisitions and internal scientific innovation, Bio-Techne has become uniquely positioned to provide a comprehensive, innovative, and flexible... Read more
Download as PDF AUGUST 08, 2018 MINNEAPOLIS, Aug. 8, 2018 /PRNewswire/ — Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies. Bio-Techne has a highly-qualified team who have full control over the... Read more
AUGUST 01, 2018 MINNEAPOLIS, Aug.1, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc. The transaction consideration includes an upfront payment of $250 million plus an additional $325 million that can be maximally earned through calendar year 2022 upon reaching certain performance milestones. With this acquisition, Minneapolis-based... Read more
JULY 24, 2018 MINNEAPOLIS, July 24, 2018 /PRNewswire/ — Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess. This evolutionary technology simplifies protein expression analysis, while speeding up time to result. Jess automates both the protein separation and immunodetection elements characteristic of traditional protein analysis... Read more
Download as PDF JULY 10, 2018 Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results MINNEAPOLIS, July 10, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of antibody-based reagents for life science and clinical research, has been validating an extensive and growing number of antibodies using... Read more